微超声与MRI靶向活检在前列腺癌风险男性中的非劣效性对比分析
在德国和奥地利三家机构前瞻性纳入203例患者,比较微超声靶向活检与多参数MRI靶向活检对临床显著前列腺癌(Grade Group >1)的检出效能。微超声靶向活检检出58/79例(73%),MRI靶向活检检出60/79例(76%),微超声对MRI靶向活检检出病例的检出比为97%(95% CI 80-116%;P = 0.023),达到非劣效。
要点
- 微超声靶向活检检出临床显著前列腺癌58/79例(73%),MRI靶向活检检出60/79例(76%)。
- 微超声对MRI靶向活检检出病例的检出比为97%(95% CI 80-116%;P = 0.023),达到非劣效。
- 仅MRI靶向检出而微超声靶向和系统取样均漏检7/79例(9%),其中3例为前部病灶、2/7位于移行区。
核心结论
- 微超声对MRI靶向活检检出病例的检出比为97%(95% CI 80-116%;P = 0.023),达到非劣效。
- 研究提示微超声活检对临床显著前列腺癌的检出可能不劣于多参数MRI。
研究设计与样本
- 前瞻性多中心研究,2019年1月至2019年12月在德国和奥地利三家机构纳入203例患者。
- 每例活检时术者对MRI报告设盲,先评估微超声靶点,揭盲后以软件辅助融合取样靶点,随后系统取样。
主要发现
- 共检出临床显著前列腺癌79例(39%)。
- 微超声靶向活检检出58/79例(73%),MRI靶向活检检出60/79例(76%),非靶向(补充取样)检出45/79例(57%)。
- 仅MRI靶向检出而微超声靶向和系统取样均漏检7/79例(9%),其中3例为前部病灶、2/7位于移行区。
- 仅微超声靶向检出5/79例(6%),仅补充取样检出4/79例(5%)。
关键数值与推荐
- 主要结局为微超声检出临床显著前列腺癌的非劣效性,要求检出比至少为MRI的80%。
- 微超声对MRI靶向活检检出病例的检出比为97%(95% CI 80-116%;P = 0.023)。
临床怎么用
- 作者认为微超声活检对临床显著前列腺癌的检出可能不劣于多参数MRI。
- 作者认为该结果对提高可及性、降低成本和加快诊断具有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of multiparametric magnetic resonance imaging (mpMRI)-directed and micro-ultrasonography (micro-US)-directed biopsy for detecting clinically significant (Grade Group >1) prostate cancer (csPCa). MATERIALS AND METHODS: A total of 203 patients were prospectively enrolled at three institutions across Germany and Austria in the period from January 2019 to December 2019. During each biopsy, the urologist was blinded to the mpMRI report until after the micro-US targets had been assessed. After unblinding, targets were then sampled using software-assisted fusion, followed by systematic samples. The primary outcome measure was non-inferiority of micro-US to detect csPCa, with a detection ratio of at least 80% that of mpMRI. RESULTS: A total of 79 csPCa cases were detected overall (39%). Micro-US-targeted biopsy detected 58/79 cases (73%), while mpMRI-targeted biopsy detected 60/79 (76%) and non-targeted (completion sampling) samples detected 45/79 cases (57%). mpMRI-targeted samples alone detected 7/79 (9%) csPCa cases which were missed by micro-US-targeted and non-targeted samples. Three of these seven were anterior lesions with 2/7 in the transition zone. Micro-US-targeted samples alone detected 5/79 (6%) and completion sampling alone detected 4/79 cases (5%). Micro-US was non-inferior to mpMRI and detected 97% of the csPCa cases detected by mpMRI-targeted biopsy (95% CI 80-116%; P = 0.023). CONCLUSIONS: This is the first multicentre prospective study comparing micro-US-targeted biopsy with mpMRI-targeted biopsy. The study provides further evidence that micro-US can reliably detect cancer lesions and suggests that micro-US biopsy might be as effective as mpMRI for detection of csPCA. This result has significant implications for increasing accessibility, reducing costs and expediting diagnosis.
引用
- Hofbauer SL, Luger F, Harland N, et al. A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer. BJU Int. 2021. PMID: 34773679. doi:10.1111/bju.15635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。